t-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-tetrahydropyridine-1(2H)-carboxylate | 162504-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-tetrahydropyridine-1(2H)-carboxylate
• 英文别名: 1-Boc-4-(2-Ethoxycarbonylvinyl)piperidine；tert-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)piperidine-1-carboxylate
• CAS: 162504-86-1
• 化学式: C₁₅H₂₅NO₄
• 分子量: 283.368
• InChiKey: XOSLGZABCJLALW-UHFFFAOYSA-N

物化性质

• 沸点：
  362.4±35.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  t-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-tetrahydropyridine-1(2H)-carboxylate 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 3-哌啶-4-丙酸乙酯
  参考文献：
  名称：

  Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

  摘要：

  We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors.A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition.Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.085
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 sodium hydride 、 二异丁基氢化铝 作用下， 生成 t-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-tetrahydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764

  摘要：

  An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764 was achieved. The key intermediate, an optically active ethynyl beta-amino ester, was synthesized efficiently by utilizing a lipase catalyzed kinetic resolution step. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.01.157

文献信息

• [EN] PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS<br/>[FR] COMPOSES DE PIPERIDINYLE LIANT SELECTIVEMENT LES INTEGRINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004020435A1

  公开（公告）日：2004-03-11

  The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.

  这项发明涉及选择性结合整合素受体的式(I)和(II)的哌啶基化合物，以及治疗整合素介导的疾病的方法，其中W、R2、Z和q在申请中有描述。
• Ester derivatives
  申请人：——

  公开号：US20030191316A1

  公开（公告）日：2003-10-09

  This invention relates to compounds which exhibit selective muscarinic M 3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); 1 [in which A signifies a group expressed by a formula (a 0 ) or (b 0 ); 2 Ar signifies optionally substituted aryl or heteroaryl; B 1 and B 2 signify aliphatic hydrocarbon; R 1 signifies fluorine-substituted cycloalkyl; R 2 , R 3 and R 4 signify lower alkyl, single bond or alkylene bonded to B 1 , or R 2 and R 3 are united to signify alkylene; R 5 and R 7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B 2 ; R 6 signifies hydrogen, lower alkyl or a group expressed as —N(R 8 )R 9 ; and X − signifies an anion].

  这项发明涉及表现出选择性肌肉M3受体拮抗作用、副作用小、适用于吸入疗法并且可用作治疗呼吸系统疾病的治疗剂的化合物，其一般式为（I）； 其中A表示由式（a0）或（b0）表示的基团； Ar表示可选择取代的芳基或杂环芳基；B1和B2表示脂肪烃基；R1表示氟取代的环烷基；R2、R3和R4表示较低的烷基、与B1结合的单键或烷基，或者R2和R3结合表示烷基；R5和R7表示氢、较低的烷基，或者与B2结合的单键或烷基；R6表示氢、较低的烷基或表示为—N(R8)R9的基团；X-表示阴离子。
• Catalytic Asymmetric Allylic Substitution with Copper(I) Homoenolates Generated from Cyclopropanols
  作者：Qi Zhang、Si‐Wei Zhou、Chang‐Yun Shi、Liang Yin

  DOI：10.1002/anie.202110709

  日期：2021.12.6

  A catalytic asymmetric allylic substitution with NHC-stabilized copper(I) homoenolates generated from cyclopropanols is developed that affords γ-chiral ketones in excellent regio- and high enantioselectivities. This process enables the generation of chiral quaternary carbon centers and features a broad substrate scope.

  开发了一种催化不对称烯丙基取代，用 NHC 稳定的铜 (I) 均烯醇化物从环丙醇生成，以优异的区域选择性和高对映选择性提供 γ-手性酮。该过程能够产生手性四元碳中心并具有广泛的底物范围。
• 4-哌啶基-1H-吡咯-3-甲酰胺类化合物盐酸盐 的合成方法
  申请人：河南科技大学第一附属医院

  公开号：CN104829592B

  公开（公告）日：2017-03-15

  本发明公开一种4‑哌啶基‑1H‑吡咯‑3‑甲酰胺类化合物盐酸盐的合成方法，先将化合物ⅠBoc‑4‑羟甲基哌啶与草酰氯反应，再将得到化合物Ⅱ与磷酰乙酸三乙酯反应，得到化合物Ⅲ；将化合物Ⅲ与对甲基苯磺酰甲基异腈反应，得到化合物Ⅳ；化合物Ⅳ与2‑(三甲硅烷基)乙氧甲基氯反应生成化合物Ⅴ；化合物Ⅴ水解得到化合物Ⅵ，化合物Ⅵ与胺基化合物反应生成化合物Ⅶ；化合物Ⅶ在四丁基氟化氨作用下得到化合物Ⅷ；化合物Ⅷ在HCl作用下得到化合物Ⅸ，即4‑哌啶基‑1H‑吡咯‑3‑甲酰胺类盐酸盐。本发明将吡咯环3,4位引入哌啶基和酰胺基，反应路线简单易行，得到的化合物具有多个活性基团，水溶性好，具有开发为医药中间体的潜力。
• Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors
  作者：Cristina Rossi、Marina Porcelloni、Piero D’Andrea、Christopher I. Fincham、Alessandro Ettorre、Sandro Mauro、Antonella Squarcia、Mario Bigioni、Massimo Parlani、Federica Nardelli、Monica Binaschi、Carlo A. Maggi、Daniela Fattori

  DOI：10.1016/j.bmcl.2011.02.085

  日期：2011.4

  We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors.A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition.Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells. (C) 2011 Elsevier Ltd. All rights reserved.